Clinical Trial Update: Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the efficacy and safety of once-daily atrasentan tablets (low and high doses) versus placebo in reducing residual albuminuria in Type …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetic Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Status: COMPLETED